MRC1 and head and neck squamous cell carcinoma: These findings underscore the clinical value of MMR testing in LA-HNSCC, which primarily lies in identifying patients who are likely to be insensitive to initial CCRT but have a high probability of benefiting from subsequent immunotherapy, thereby informing personalized sequential treatment strategies.